Answer

Drivers of Scent Recovery; 2H Evolution of Fine Fragrance & Consumer Fragrance; and R&D Plan to Support 2027

1) What are the drivers of IFF “Scent” recovery?

Management attributes the recovery to (a) rebuilding the R&D capability and pipeline, (b) improving commercial execution and market share gains, and (c) compositional/temporary factors in Fragrance Ingredients plus stabilization efforts in Fine Fragrance.

A. R&D and go-to-market capability rebuilt (core recovery driver)

IFF describes a multi-year initiative to get the balance right (including investing in R&D) and grow market share back within Scent. ¹
Management states that 2.5 years ago the R&D pipeline was “not what it should have been”, whereas today IFF has a “very strong R&D capability,” strong R&D team, leading-edge perfumers, and a pipeline of molecules and delivery systems. ²

B. Fine Fragrance stabilization amid Middle East volatility

For Fine Fragrance, IFF reports the team managed Middle East uncertainty/volatility such that Fine Fragrance finished slightly positive vs expectations of mid-single-digit decline. ³
The company also references that the Middle East crisis continues and that it is factoring in a softer Q3 for Fine Fragrance. ³

C. Fragrance Ingredients rebound helped by favorable comps and synthetics capture (but expected to normalize)

Scent’s Q2 growth is described as driven by Fragrance Ingredients: Scent sales were up 8%, with Fragrance Ingredients growing north of 20%; management notes this included year-over-year delta against a prior-year period that was down 10% or more. ³
Management also says this growth reflected strategic use of the synthetics portfolio to capture more sales amid macro and supply chain disruptions and higher Brent crude prices. ³
Importantly, IFF expects Fragrance Ingredients to normalize as conditions settle, specifically shifting back toward higher value-added ingredients vs traditional synthetics, and that this normalization is included in the forecast for the second half. ³

D. Operating performance support: volume + productivity

On the segment, IFF reports Scent delivered $665 million sales (+8%) and EBITDA of $134 million (+5%), with profitability driven by volume growth and productivity gains. ⁴
At the consolidated segment level, IFF attributes profitability improvements to volume growth and continued productivity gains/execution. ⁵

2) How will Fine Fragrance and Consumer Fragrance evolve in the second half?

IFF provided explicit “second half” directional growth expectations for each Scent sub-segment, plus normalization commentary.

2A. Fine Fragrance evolution in 2H (softer Q3, stronger Q4; mid-single-digit H2)

IFF expects Fine Fragrance to be a little softer in Q3 but stronger in Q4. ⁶
On a second-half basis, management frames Fine Fragrance growth as mid-single-digit range. ⁶
The company links near-term softness to Middle East-related uncertainty and a large Q3 comparable, noting Fine Fragrance grew 20% year-over-year in Q3 last year (a ~20% comp). ³

Interpretation from the transcript: The recovery path for Fine Fragrance is not “straight up” in Q3; it’s more of a lumpy normalization (Q3 down/softening, then Q4 catch-up) against difficult comparisons and ongoing regional volatility. ⁶³

2B. Consumer Fragrance evolution in 2H (low single-digit normalization)

IFF expects Consumer Fragrance to be in the low single-digit range for the broader go-forward second-half trajectory. ⁶
Management says Q2 was strong (high single-digit), but expects it to normalize to a low single-digit number going forward. ⁶

Also relevant: IFF cites that the team rebuilt R&D capability and go-to-market approach with customers and is driving market share gains—a supportive underlying element for Consumer Fragrance performance even as growth normalizes from the strong quarter. ⁶

2C. Fragrance Ingredients (important “Scent recovery” component) normalizes in 2H

While your question focuses on Fine and Consumer Fragrance, IFF’s overall “Scent recovery” depends heavily on Fragrance Ingredients (because it drove Q2 and sets the tone for mid-year vs second-half results):

IFF states Fragrance Ingredients was very strong in Q2 and will normalize on a go-forward basis, such that it will be slightly under pressure year-over-year. ⁶
The company also reiterates the drivers: Q2 included capture of synthetics under macro/supply chain conditions, and as those settle, the business shifts back toward higher-value-added ingredients. ³

3) Plan for R&D to support 2027

IFF’s excerpts describe both the state of R&D today and the strategic direction for how R&D improvements should translate into competitive positioning into future years (including 2027).

A. Current R&D capability and pipeline have been rebuilt since ~2.5 years ago

IFF explicitly contrasts the prior pipeline problem (“2.5 years ago was not what it should have been”) with the current state: strong R&D capability, leading-edge new Fine Fragrances and Consumer Fragrances, and a pipeline of molecules and delivery systems. ²

B. Management’s “2027 support” framing: competitive position strengthens over time

On business evolution, IFF says that the operational/portfolio shift on Fragrance Ingredients toward higher-value natural products is underway; it will take more time, and while it is not expected to be visible in the second half of this year, IFF expects a “really strong competitive position” as we go into next year and the year after. ⁶
While the transcript doesn’t explicitly say “2027” in that sentence, “the year after” next year aligns with the 2027 horizon discussed in your question context. ⁶

C. R&D supports the commercialization loop (invest → win → reinvest)

The company’s strategic language ties innovation to reinforcing growth and margins: innovation is an “important pillar” because it creates a circle where IFF makes investments, gets better growth, expands margin, and then can reinvest. ⁷

D. Specific R&D/growth capability elements mentioned

The transcript credits progress not only to “R&D capability,” but also to rebuilding compounds capability for Fine/Consumer and rebuilding go-to-market approach with customers, in order to drive market share gains. ⁶

Overall conclusion on the R&D plan toward 2027: The plan described in the filings is less about a single incremental program and more about sustaining a rebuilt R&D engine—pipeline depth, perfumer capability, molecules/delivery systems, compounds strategy, and customer go-to-market integration—so that near-term recovery (2H) can transition into stronger competitive positioning into subsequent years (including the 2027 timeframe). ⁶²⁷

Summary (direct answers)

Drivers of Scent recovery: rebuilt balance including R&D investment, stronger R&D pipeline and perfumer output, improved commercial go-to-market execution/market share gains, and stabilization efforts in Fine Fragrance amid Middle East volatility; plus Fragrance Ingredients’ Q2 surge from favorable comps and synthetics capture, which is expected to normalize in 2H. ¹⁶²³
2H evolution:
- Fine Fragrance: softer Q3, stronger Q4; mid-single-digit growth for the second half; influenced by Middle East volatility and a ~20% Q3 prior-year comp. ⁶³
- Consumer Fragrance: strong Q2 (high single digits) expected to normalize to low single digits on a go-forward second-half basis. ⁶
- Fragrance Ingredients (key context): normalize; slightly under pressure YoY vs very strong Q2; shift back toward higher-value-added ingredients included in the 2H forecast. ⁶³
R&D plan to support 2027: management indicates the R&D “engine” has been rebuilt (molecules + delivery systems + leading-edge product development), and that innovation and go-to-market reinforcement create a loop supporting sustained growth and margin expansion into the next years, with competitive strength expected “next year and the year after” (covering the 2027 horizon). ⁶²⁷

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

IFF Scent Recovery Accelerates; 2H 2026 Outlook and 2027 R&D

Sources used

Research question

Answer

Drivers of Scent Recovery; 2H Evolution of Fine Fragrance & Consumer Fragrance; and R&D Plan to Support 2027

1) What are the drivers of IFF “Scent” recovery?

A. R&D and go-to-market capability rebuilt (core recovery driver)

B. Fine Fragrance stabilization amid Middle East volatility

C. Fragrance Ingredients rebound helped by favorable comps and synthetics capture (but expected to normalize)

D. Operating performance support: volume + productivity

2) How will Fine Fragrance and Consumer Fragrance evolve in the second half?

2A. Fine Fragrance evolution in 2H (softer Q3, stronger Q4; mid-single-digit H2)

2B. Consumer Fragrance evolution in 2H (low single-digit normalization)

2C. Fragrance Ingredients (important “Scent recovery” component) normalizes in 2H

3) Plan for R&D to support 2027

A. Current R&D capability and pipeline have been rebuilt since ~2.5 years ago

B. Management’s “2027 support” framing: competitive position strengthens over time

C. R&D supports the commercialization loop (invest → win → reinvest)

D. Specific R&D/growth capability elements mentioned

Summary (direct answers)

References

Keep Reading

IFF Scent Recovery Driven by R&D, 2H 2026 Outlook and 2027 Plan

Keep Reading

Keep Reading

IFF Scent Recovery Driven by R&D, 2H 2026 Outlook and 2027 Plan

IFF's Scent Recovery Gains Momentum in 2H 2026 as R&D Drives 2027 Plan

IFF Scent Recovery Fueled by R&D Strength; 2H Outlook and 2027 Plan, Q2 2026

IFF Scent Recovery Driven by Operational Gains, Fragrance Strength, and 2027 R&D Plan

IFF's Scent Recovery Gains Momentum with R&D and H2 Outlook for 2026

IFF Scent Recovery Driven by R&D Strength and Market Share Gains

IFF Scent Recovery Driven by Ingredients Surge, 2H 2026 Outlook and 2027 R&D Plan

IFF Scent Recovery Gains Momentum in Q2, H2 Outlook, and 2027 R&D Plan

IFF Scent Recovery Gains Momentum; H2 Outlook and 2027 R&D Plan

IFF Scent Sees Recovery Driven by R&D and Market Share, With 2H Fragrance Outlook

Scent Recovery Drivers Drive IFF's H2 Outlook and 2027 R&D Plan

Analyzing IFF Q1 2026 Earnings Surpassing Expectations Due to Volume Growth